Health TrialsbyHealthPanel

Comparison of the Postoperative Analgesic Efficacy of SAP and SPSIP Blocks in Patients Undergoing Mammoplasty

ConditionsPostoperative PainPostsurgical PainBreast Pain
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorAbant Izzet Baysal University

About this trial

The aim is to compare the postoperative analgesic efficacy of serratus anterior plane block (SAPB) and serratus posterior superior intercostal plane block (SPSIPB) in patients undergoing mammoplasty surgery. To this end, a double-blind, randomized, controlled study has been designed. Female patients aged 18-65 years who will undergo mammoplasty surgery will be included in the study. Postoperative pain levels, opioid consumption, duration of analgesic requirement, and patient satisfaction will be evaluated in patients who receive fascial blocks for analgesic purposes.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients aged 18-85 years

Patients undergoing elective mammoplasty

ASA physical status I-II

Disqualifiers

Patients who refuse to participate

Mentally disabled patients

Presence of infection at the injection site

Patients with coagulopathy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Serratus Anterior Plane Block

    Procedure/Surgery

    Application of ultrasound-guided serratus anterior plane block for perioperative analgesia for mammoplasty operations. Serratus anterior plane block will be administered under general anesthesia before the surgery Drug: Bupivacaine (Block Drug) For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for each side.

  • Serratus Posterior Superior Intercostal Plane Block

    Procedure/Surgery

    Application of ultrasound-guided serratus anterior plane block for perioperative analgesia for mammoplasty operations. Serratus posterior superior intercostal plane block will be administered under general anesthesia before the surgery Drug: Bupivacaine (Block Drug) For block performances, 0,25% Bupivacaine will be used at 0,5 ml/kg (max. 20cc) for each side.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: SAPB GroupActive comparator 1 intervention
Group B: SPSIPB GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Total opioid consumption

Tramadol will be prepared at a concentration of 10 mg/mL, and patient-controlled analgesia (PCA) will be administered without a basal infusion, using a lock-out interval of 20 minutes and a bolus dose of 20 mg.

Time frame
0, 1, 6, 12 and 24 hours
2

Postoperative pain scores (Numerical rating scale: NRS),Between 0 and 10 points (11 points in total), as the score increases, the pain intensity increases.

Postoperative 24 hours period. Patients' pain scores will be questioned at 0, 1, 6, 12 and 24 hours.

Time frame
0, 1, 6, 12 and 24 hours

Secondary outcomes

1

Time to first analgesic requirement

Time from end of surgery to first analgesic requirement (min)

Time frame
24 Hour
2

Patient satisfaction score

Overall patient satisfaction scores will be assessed using a 5-point Likert scale,Minimum value: 1, Maximum value: 5, where higher scores indicate greater satisfaction.

Time frame
24 Hour

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Abant Izzet Baysal University

Lead sponsor

Karabuk Training and Research Hospital

Collaborator

Başakşehir Çam & Sakura City Hospital

Collaborator

Istanbul Medipol University Hospital

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: